Raymond James analyst Christopher Raymond initiated coverage of Aktis Oncology with a Strong Buy rating and $40 price target. The firm thinks Aktis' miniprotein-enabled radioligand therapy platform is highly differentiated, potentially offering better efficacy, safety, and developmental flexibility than earlier generation radiotherapy approaches in a targeted radiopharma field that is "growing rapidly," the analyst tells investors.
